The Next Orphan Drug Multibagger and Future Obesity Champion?

Before you go, we thought you'd like these...
Before you go close icon

The newest kid on the biotech block is Zafgen , which successfully IPO'd this month. Shares popped over 20% on its opening day and have held strong since.

Zafgen has a small pipeline, but it does have a drug for Prader-Willi Syndrome, an orphan disease with an unmet need, in late-stage development. In addition to the excitement that beloranib could treat this genetic disorder, there is the added benefit its unique mechanism could make it an incredible obesity fighter as well.

In this episode of Market Check-Up, The Motley Fool's health care-focused investing show, analysts David Williamson and Michael Douglass discuss Zafgen's pipeline, its lead drug potential, and why investors in obesity stocks Orexigen  Arena , and VIVUS  should be concerned about the newest entry to the obesity drug wars.

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and with more accuracy than anyone else. There's a product in development that will revolutionize how we treat a common chronic illness and could even change the entire health industry. Analysts are already licking their chops at the sales potential. To outsmart Wall Street and realize multibagger returns, you need The Motley Fool's new free report on the dream team responsible for this game-changing blockbuster. Click here now.


The article The Next Orphan Drug Multibagger and Future Obesity Champion? originally appeared on

David Williamson owns shares of AbbVie. Michael Douglass and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

People are Reading